Background and objectives Little is known about the utility of self-rated general health assessments in persons with moderate-to-severe CKD. This study examined the ability of a single self-rated health measure to predict allcause mortality and kidney disease progression in a cohort of 443 patients with stages 3-4 CKD, recruited between 2005 and 2011, and followed until the end of 2012. The performance of models incorporating self-rated health measures was compared with previously published predictive models and more complex models comprising a multibiomarker panel.
Introduction
CKD, defined by an eGFR,60 ml/min per 1.73 m 2 or the presence of albuminuria, is one of the fastestgrowing chronic health conditions worldwide, particularly among older people (1, 2) . CKD now affects approximately one eighth of the United States population (2, 3) and is associated with substantially increased risks of ESRD, cardiovascular events, and premature death (4) (5) (6) (7) .
However, predictive models based on multiple biomarkers are challenging to implement into clinical workflow due to their cost and complexity, the length of time required to obtain results, and the issue of how to manage missing information. Meanwhile, subjective health measures, including self-rated health assessment, are rapidly administered, widely used within clinical and epidemiologic research settings, and correlate well with important outcomes (8) (9) (10) . Strong relationships between self-rated health measures and mortality have been reported in general adult and elderly populations (8) (9) (10) (11) (12) .
The ability of self-rated health measures to accurately predict adverse clinical events has not been widely assessed in persons with CKD, who account for nearly 12% of United States adults. To address this knowledge gap, we examined the ability of a single self-rated health measure to predict all-cause mortality and kidney disease progression in a prospective cohort of patients with CKD. We were particularly interested in comparing the performance of models incorporating self-rated health measures to more complex models that incorporated biomarkers.
Materials and Methods

Study Population
The Seattle Kidney Study (SKS) is a nephrology clinic-based, prospective cohort study of 685 participants with CKD. Participant recruitment began in 2004 from outpatient nephrology clinics at the Veterans Affairs Puget Sound Health Care System (VAMC), followed by additional clinics at Harborview Medical Center (HMC) and the University of Washington (UW). Specific details of the SKS, including general inclusion and exclusion criteria, were previously described (13) . This study focused on participants with moderate-to-severe CKD (stages 3 and 4; eGFR 15-59 ml/min per 1.73 m 2 ) and thus we excluded 225 participants who had mild CKD (eGFR$60 ml/min per 1.73 m 2 with albuminuria) or highly advanced disease (eGFR,15 ml/min per 1.73 m 2 ) at baseline. We further excluded 17 participants with missing self-rated health at baseline. The analytic cohort comprised the remaining 443 participants. The UW and VAMC institutional review boards approved the study protocol.
Assessment of Self-Rated Health
Study coordinators mailed the Kidney Disease Quality of Life (KDQOL) instrument (Rand) to participants before their scheduled study visits. All analyses presented here are based on the first question on the KDQOL instrument administered at baseline, which asks "In general, would you say your health is. . .?" followed by five answer choices ranging from excellent (score of 5) to very good, good, fair, or poor (score of 1). Based on previous studies of self-rated health and the limited number of participants who responded "excellent" (n=5), "very good" (n=20), or "poor" (n=30), we dichotomized responses into good to excellent versus fair to poor for regression analyses and prediction evaluation (14) (15) (16) (17) .
Outcome Ascertainment
Serum cystatin C levels were measured from frozen serum samples stored at 270°C using either a particleenhanced immunonephelometric assay (Gentian A/S, Norway) with a clinical chemistry analyzer (DXC600; Beckman Coulter, Miami, FL) or a nephelometer (BNII; Siemens Healthcare Diagnostics Inc, Deerfield, IL). We certified the Gentian assay using cystatin C reference material (ERM-DAY7/IFCC) per its Certificate of Analysis and corrected by weight to yield a cystatin C concentration of 5.48 mg/L (uncertainty of 0.15 mg/L). We then calibrated the Siemens assay to the Gentian assay (gold standard) in a subset of 40 SKS participants who had serum samples simultaneously measured on both assays (r 2 =0.98). The assays are stable through several freeze-thaw cycles (18) . Serum creatinine was measured by the modified rate Jaffe method with an assay traceable to isotope dilution mass spectrometry, respectively. We calculated eGFR annually using the combined cystatin and creatinine-based CKD Epidemiology Collaboration equation (19) . Incident ESRD events, defined as the first occurrence of initiation of maintenance dialysis or receipt of a kidney transplant, were identified during twice-yearly surveillance calls and in-person follow-up examinations. Study coordinators specifically inquired about the initiation of dialysis since the previous study encounter.
The primary renal outcome was the time to first occurrence of .30% loss of baseline eGFR (20) or initiation of RRT (chronic dialysis or kidney transplantation) over follow-up.
Deaths were identified from proxies during surveillance calls and during scheduling calls for annual visits. Because kidney disease progression and mortality are competing outcomes in CKD patients, a combined adverse event end point (defined as the first occurrence of initiation of dialysis, kidney transplantation, loss of .30% of eGFR, or death from any cause during the study) was derived to evaluate potential informative censoring.
Covariate Ascertainment
Prevalent conditions were determined based on participant responses to questionnaires, and from hospitalizations that occurred after initial SKS enrollment but before initial assessment for this study, and were defined as previously described (13) . Study staff assessed medication uses by computerized pharmacy records (VAMC) or by the inventory method (HMC and UW) (21) .
Marital status, education attainment, work status, exercise frequency, smoking status, and alcohol use were determined via baseline lifestyle questionnaires. Serum, plasma, and urine samples were stored at 270°C until measurement. General chemistries were measured on a Beckman Coulter DxC autoanalyzer (Beckman Coulter, Brea, CA). Urine albumin and creatinine were measured in spot morning or overnight urine collections by a timed end point method and with the modified rate Jaffe method. 
Statistical Analyses
Baseline descriptive statistics on demographics, medical history, and clinical, laboratory, and lifestyle characteristics were examined by self-rated health levels. We report continuous variables as means6SDs or medians and interquartile ranges, and categorical variables as numbers and percentages.
To identify predictors of self-rated health, we assessed candidate patient characteristics for association with baseline self-rated health using forward stepwise logistic regression in which baseline self-rated health served as the dependent variable. Each characteristic (from Table 1 ) was regressed on self-rated health, and we ranked the characteristics from lowest to highest univariate Akaike information criterion (AIC) (22) . Next, we combined patient characteristics into one model, adding each characteristic in the AIC-based order. We retained variables whose inclusion in the model reduced the AIC; if a variable did not reduce the AIC when it was added, it was dropped. Using the AIC has the appeal of not having to set arbitrary criteria for entering and removing variables. The likelihood ratio test comparing each successive model with the nested model without the parameter in question was used to obtain a P value.
We calculated survival time as the time from the date of baseline examination until death, the kidney disease progression end point, or, for the combined end point, whichever occurred first. We censored participants when they became lost to follow-up (n=13) or at the end of the study period on February 27, 2013. For the mortality end point, we calculated unadjusted incidence rates as the number of events divided by personyears at risk. For the kidney disease progression and combined end points, we calculated unadjusted incidence rates as the number of events divided by person-visits at risk. Cox proportional hazards regression and discrete-time proportional hazards models were used to estimate the relative hazard of mortality, and of kidney disease progression and the combined mortality/progression end point, respectively, after adjustment for covariates selected a priori, which we hypothesized might confound the association between self-rated health, the multibiomarker panel, or the traditional predictive risk factors and the outcomes of interest. We verified that the assumption of proportional hazards was satisfied.
Regression models were constructed in order to progressively examine the confounding effects of patient characteristics on the association of self-rated health and time to death or kidney disease progression. Model one adjusted for age, sex, race/ethnicity, work status, and education attainment. Model two additionally included (1) covariates identified a priori based on suspicion that it may confound the association between self-rated health and mortality or kidney disease progression (body mass index, systolic BP, diabetes status, prevalent coronary artery disease status, smoking status, eGFR, and urine albumin to creatinine ratio [log-transformed]), and (2) additional characteristics independently associated with self-rated health, identified from stepwise regression methods (b-blocker use and current alcohol use).
Because previous studies found stronger associations of self-rated health with mortality among men and among younger individuals (8), we conducted sensitivity analyses stratified by sex and age group (,65 years versus $65 years). To examine whether associations varied by sex, age, and baseline eGFR, we used likelihood ratio tests comparing models with and without multiplicative interaction terms. P values from these tests were nonsignificant (all P values .0.40) indicating statistically similar prediction across sex, age, and baseline eGFR in this cohort. Therefore, we present results only for the complete study population.
Model Performance
To compare the discrimination performance of the models, receiver operating characteristic curves were obtained with unadjusted logistic regression models that examined allcause mortality, kidney disease progression events, and the combined end point through 3 years of follow-up (23) . A logistic regression procedure was used to determine test characteristics of each predictive model at the cut-point that predicted the probability of the outcome at $0.5. For analyses of predictive performance, three predictive models were examined for each outcome: kidney disease progression, all-cause mortality, and the combined event. Across outcomes, only the base models differed, with subsequent models being conserved. For prediction of the risk of allcause mortality, the base model was composed of age, race, sex, eGFR, albuminuria, and the Framingham risk score (24) . The Framingham risk score was derived for each individual using the sex-specific prediction formulas proposed by Wilson et al. based on traditional cardiovascular risk factors (age, total and HDL cholesterol categories, BP categories, diabetes mellitus, and smoking status) (24) . For prediction of progression of CKD, the base model included age, sex, eGFR, albuminuria, serum calcium, serum phosphate, serum bicarbonate, and serum albumin as previously developed and validated by Tangri and collaborators in large cohorts of Canadian patients with stages 3-5 CKD (25) . We incorporated race (white, black, or other) into this model, because previous studies have observed marked racial differences in risk of death and ESRD. For the combined end-point analyses, the base model comprehensively collected all factors from the base models for kidney disease progression and all-cause mortality. For all end points, the second model combined age, sex, race/ethnicity, eGFR, albuminuria, and added laboratory assessment of a multibiomarker panel. The multibiomarker panel included eight biomarkers from biologic pathways associated with increased morbidity and mortality: cystatin C (26), CRP (log-transformed) (27), 25(OH)D (28), PTH (29), FGF-23 (log-transformed) (30), hemoglobin (31), uric acid (32), and anion gap (33) . The final predictive model combined age, sex, race, eGFR, albuminuria, and the participant's response to the self-rated health question. Because it has been shown that self-rated health in combination with a multibiomarker panel predicts all-cause mortality better than either alone in the general population, we estimated the predictive performance of a model that combined the multibiomarker panel with the self-rated health model (11) . Model performances were compared using a nonparametric area under the curve (AUC) analysis (34) . Unadjusted associations between each biomarker and the self-rated health assessment were evaluated with Pearson's correlation coefficients. STATA software (version 13.0; College Station, TX) and the R 2.12.1 package were used for all analyses.
Results
Baseline Characteristics
At baseline, the mean age was 62 years and 17% of participants were women. Participants with lower (worse) self-rated health status were more likely to be African American, unemployed, and have diabetes mellitus or coronary artery disease (Table 1) . Self-rated health status was not correlated with eGFR, nor was it related to serum calcium, bicarbonate, anion gap, or hemoglobin concentrations. Baseline characteristics that were independently associated with self-rated health were b-blocker use, prevalent diabetes, work status, body mass index, and current alcohol use ( Table 2) .
Self-Rated Health, Mortality, and ESRD Events
During a median follow-up of 3.3 years (interquartile range, 1.9-4.6 years),118 participants died and 138 participants had progressive kidney disease (66 initiated dialysis, one received a kidney transplant, and 71 experienced a .30% loss of eGFR) ( Table 3) . Forty-one participants reached the kidney disease progression end point before death during the study.
Mortality rates and incidence rates of kidney disease progression were higher among participants with fair-topoor health status, compared with participants with goodexcellent self-rated health (Table 3) . Fair-to-poor self-rated health status was associated with a significantly higher risk of mortality (hazard ratio [HR], 2.76; 95% confidence interval [95% CI], 1.28 to 5.89), kidney disease progression (HR, 1.94; 95% CI, 1.49 to 2.56), and the combined end point (HR, 2.21; 95% CI, 1.66 to 2.96) (Table 3) , relative to good-toexcellent self-rated health, after full adjustment for covariates. 
Prediction of Adverse Events
Sensitivity and specificity for the base model, multibiomarker panel, and self-rated health model to predict kidney disease progression and mortality at 3 years were assessed across a range of cutoff values (Figure 1 ). For 3-year mortality prediction, the self-rated health model (AUC, 0.80; 95% CI, 0.76 to 0.85) had significantly higher AUCs than the base model (AUC, 0.71; 95% CI, 0.66 to 0.76) and the multibiomarker panel model (AUC, 0.74; 95% CI, 0.68 to 0.80) (P=0.03 and P=0.04, respectively) ( Table 4) .
Similarly, for kidney disease progression prediction, both the multibiomarker panel (AUC, 0.89; 95% CI, 0.85 to 0.94) and the self-rated health models (AUC, 0.93; 95% CI, 0.88 to 0.97) had higher predictive performance than the base model (AUC, 0.88; 95% CI, 0.83 to 0.92) (P=0.04 and P=0.03, respectively), yet there was no significant difference between the multibiomarker panel and the self-rated health models (P=0.08). A model that included both the biomarker panel and the selfrated health model did not improve the area under the receiver operating characteristic curve, across any end point.
Discussion
In this clinic-based cohort study of participants with moderate-to-severe CKD, we found that lower self-rated health was significantly associated with greater risks of allcause mortality and kidney disease progression, independent of traditional risk factors. Furthermore, the single self-rated health question predicted mortality and kidney disease progression more precisely than previously published predictive models. Improvements in risk prediction using selfrated health were similar or greater than improvements in prediction garnered from a panel of biomarkers.
Little published data exist on the association of self-rated health and adverse clinical outcomes among patients with moderate-to-severe CKD. Our study's risk estimates for mortality were similar to those previously reported in other (less diverse) populations (35, 36) . Among 1443 incident dialysis patients in The Netherlands, poor and fair self-rated health were associated with greater risks of death, similar in magnitude to those observed in our study, with adjusted HRs of 3.56 (95% CI, 1.71 to 7.42) for poor and 2.09 (95% CI, 1.06 to 4.12) for fair. In the largest study to date, with nearly 30 years of follow-up, Bopp et al. observed an independent, graded association of self-rated health with mortality among 8000 community-dwelling participants from the Swiss National Research Program (37) .
We found that self-rated health better predicted kidney disease progression than total mortality. The degree to which self-rated health can act as a predictor of events depends on the comprehensiveness and accuracy of the information that the individual incorporates into his or her self-rating. Several studies have shown that the association of self-rated health with mortality is stronger when the cause of death is a condition Sensitivity and specificity estimated at the cut-point that predicted the probability of the outcome at $0.5. Pearson's correlation coefficients between the self-rated health assessment and each of the biomarkers from the multibiomarker panel are as follows (higher value refers to worse self-rated health): r=0.14 for cystatin C, r=0.08 for logCRP, r=20.16 for 25-hydroxyvitamin D, r=0.10 for parathyroid hormone, r=0.11 for fibroblast growth factor-23 (log-transformed), r=20.12 for hemoglobin, r=0.09 for uric acid, and r=0.03 for anion gap. AUC, area under the curve; CRP, C-reactive protein.
a The mortality base model was composed of age, race, sex, eGFR, albuminuria, and the Framingham Risk Score (n=443). b The multibiomarker panel included cystatin C, CRP (log-transformed), 25-hydroxyvitamin D, parathyroid hormone, fibroblast growth factor-23 (log-transformed), hemoglobin, uric acid, and anion gap (n=210). c The self-rated health model combined age, sex, race, eGFR, albuminuria, and the participant's response to the self-rated health question (n=443). The multibiomarker panel plus self-rated health model comprised 210 participants.
of which the respondent is likely to have known when giving the health assessment (38, 39) . Thus, participants in our study may have been more acutely aware of risks for progressing to ESRD than dying. The link between self-rated health and adverse outcomes, although well established, is poorly understood. Two small trials, of a dance intervention in adolescent girls (40) and a combined physical activity/dietary modification program in community-dwelling adults in Japan (41) , have shown potential modifiability of self-rated health. In population studies, self-rated health is a comprehensive, inclusive, and informative measure of health status (42) . The most plausible explanation for the strong independent association of selfrated health with adverse events is that self-reported measures reflect aspects of health and illness not fully captured by common health indicators such as comorbid medical diagnoses, laboratory tests, or clinician assessments of health status. Self-rated health can reflect a holistic self-perception of an individual's health that blends prior health history, current kidney disease and comorbid illness burden, and expectations for future health, which may be involved in the biologic pathways underlying adverse clinical outcomes.
Our study was strengthened by a well characterized, prospective sample of patients with CKD. Our study also has several limitations. The study cohort was limited to participants from a clinic-based study of CKD; compared with the general CKD population, these individuals may be likely to be more health-conscious, more likely to incorporate relevant information into their self-rated health, and more aware of their risks of clinical outcomes. This may limit the generalizability of our findings. The preponderance of male participants in our study, stemming from the inclusion of the VAMC study site, may have interfered with our ability to detect potential sex-related differences in the associations of self-rated health and important outcomes. Broadly inclusive future studies are warranted. The use of a single annual eGFR is expected to lead to misclassification in the outcome of decline in kidney function. However, misclassification in this study is likely to be nondifferential, leading to a bias of results toward the null. Finally, although poor self-rated health appears to identify patients at high risk of adverse health outcomes, it may not readily identify the most appropriate treatments to mitigate these risks.
In conclusion, a single, easily obtained measure of selfrated health helps to identify patients with CKD at high risk of mortality and kidney disease progression. Self-rated health assessment could be incorporated into patient registration, nursing intake, or clinical evaluations to provide a rapid, inexpensive, and efficient tool for identifying patients who might benefit from more intensive surveillance and/or risk factor management. Further research is needed to determine the optimal way to incorporate assessment of self-reported health into clinical practice, as well as to investigate whether interventions that optimize measures of self-reported health translate into improved outcomes for patients.
